{"denoms":[{"counts":[{"groupId":"BG000","value":"21"}],"units":"Participants"}],"groups":[{"description":"(1) Induction Chemo A; Two 21-day cycles of Gemcitabine 1000 mg/m2 days 1, 8, Navelbine 20 mg/m2 day 1, 8; Doxil 15 mg/m2 Days 1, 8, Granulocyte-colony stimulating factor(G-CSF) Days 4-6 and 10-15 (2) Induction Chemo B: Two 21-day cycles of Cyclophosphamide 2000 mg/m2 day 1; Doxorubicin 50 mg/m2 day 1; Vincristine 1.4 mg/m2 day 1; Prednisone 100 mg/m2 days 1-5; Methotrexate 3000 mg/m2 IV over 4h day 15; Leucovorin rescue (3) Disease Evaluation (4) High-dose Consolidation Chemo, high dose Ara-C, Denileukin diftitox (Ontak) and Stem Cell Collection (5) Consolidation Cytarabine 2000 mg/m2 IV over 2 h q 12h days 1-4, Etoposide 40 mg/m2 continuous intravenous infusion days 1-4, Denileukin Diftitox (Ontak) 9 mcg/kg/day days 6-10, G-CSF 10 mcg/kg/day day 14+, Stem cell collection day 22 (6) Autologous Stem Cell Transplant Carmustine 550 mg/m2 day 1-6, Etoposide 60 mg/kg IV over 4h day -4, Cyclophosphamide 100 mg/kg day -2, Stem cell infusion day 0 (7) Post-transplant: Denileukin diftitox","id":"BG000","title":"Treatment Plan"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"26","upperLimit":"68","value":"58"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"Angioimmunoblastic T-cell lymphoma (AILT)"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Peripheral T-cell lymphoma (PTCL) not classified"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Enteropathy-associated T-cell lymphoma"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Subcutaneous panniculitis-like T-cell Lymphoma"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Hepato-Splenic gamma-delta T-cell Lymphoma"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Anaplastic large cell lymphoma, ALK-"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Histology","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Bone Marrow"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Skin"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Bone"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Gastrointestinal"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Lung"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Liver"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Thyroid"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"No extranodal site"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Extranodal Sites","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Stage I/II"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Stage III"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Stage IV"}]}],"description":"The American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) maintain the classification system as a tool for doctors to stage different types of cancer based on certain standards. The stage refers to the extent of your cancer, such as how large the tumor is, and if it has spread. A cancer is always referred to by the stage it was given at diagnosis and is assigned a roman numeral from 0 to IV, where stage 0 is the least severe and stage 4 (IV) is the more severe and the cancer is more advanced than in the lower stages","paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Lactate Dehydrogenase (LDH)> normal","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"}],"title":"Score of 2"},{"measurements":[{"groupId":"BG000","value":"12"}],"title":"Score of 3"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Score of >=4"}]}],"description":"The International Prognostic Index (IPI) is a clinical tool developed by oncologists to aid in predicting the prognosis of patients. The score range is 0-5 with lower scores indicating a lower risk of death and higher scores indicating a greater risk of death.","paramType":"COUNT_OF_PARTICIPANTS","title":"International prognostic index (IPI) score","unitOfMeasure":"Participants"}]}